IDH1 and central nervous system cancer: To do this, we integrated an additional set of 1,300 tumor-specific probes that discriminated the pan-glioma primary cohort into two macro groups: the LGm1/LGm2/LGm3 DNA methylation macro group harboring the IDH1 or IDH2 mutation versus the LGm4/LGm5/LGm6 DNA methylation macro group comprising glioma samples carrying IDH-wild-type (Ceccarelli et al., 2016).